Let the delusional drive it to 20 or 100 - I'll take that over 4.
Only going to get there if Gali works. A Gali failure means only assigned value for HAE and Peramivir. PNH is a few years out and HAE market research might be incorrect so a lot of waiting until real results roll in. PNH revs of 4B plus 7 other 1B indications is great speculation on Stonehouse's part, but we seem to be the stock where the tutes aren't going to budge without real proof and sales.
It wasn't too long ago where Ph3 HAE was slammed when we are at 9.00, then the BCRX research team came back and showed longer term results were on par with existing therapy. The tutes might be calling BS until they see conversions to Oraldeyo.
Weren't they kinda pressed into trying the pill form after the early liquid Avoralstat form didn't cut it? Good think they stayed diligent otherwise we would be back below 2.